Aneuploidy drives lethal progression in prostate cancer.
aneuploidy
lethal disease
prostate cancer
transcriptome
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
04 06 2019
04 06 2019
Historique:
pubmed:
16
5
2019
medline:
24
3
2020
entrez:
16
5
2019
Statut:
ppublish
Résumé
Aneuploidy, defined as chromosome gains and losses, is a hallmark of cancer. However, compared with other tumor types, extensive aneuploidy is relatively rare in prostate cancer. Thus, whether numerical chromosome aberrations dictate disease progression in prostate cancer patients is not known. Here, we report the development of a method based on whole-transcriptome profiling that allowed us to identify chromosome-arm gains and losses in 333 primary prostate tumors. In two independent cohorts (
Identifiants
pubmed: 31085648
pii: 1902645116
doi: 10.1073/pnas.1902645116
pmc: PMC6561291
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
11390-11395Subventions
Organisme : NCI NIH HHS
ID : P50 CA090381
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014051
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA228696
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA113913
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA136578
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA006516
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA206157
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM118066
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA167552
Pays : United States
Déclaration de conflit d'intérêts
Conflict of interest statement: P.W.K. reports ownership interest in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences, and Tarveda Therapeutics, is a company board member for Context Therapeutics LLC, is a consultant/advisory board member for BIND Biosciences, Inc., BN Immunotherapeutics, DRGT, GE Healthcare, Janssen, Metamark, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics, and Thermo Fisher, and serves on data safety-monitoring boards for Genentech/Roche and Merck.
Références
Ann Epidemiol. 2000 Feb;10(2):125-34
pubmed: 10691066
Cancer Res. 2001 Nov 15;61(22):8143-9
pubmed: 11719443
Cancer Res. 2004 Oct 1;64(19):6941-9
pubmed: 15466185
Int J Cancer. 2007 Oct 1;121(7):1571-8
pubmed: 17450530
Science. 2008 Oct 31;322(5902):703-9
pubmed: 18974345
J Clin Oncol. 2009 Jul 20;27(21):3459-64
pubmed: 19433685
Proc Natl Acad Sci U S A. 2009 May 26;106(21):8671-6
pubmed: 19458043
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Biochim Biophys Acta. 2012 Jul;1819(7):784-93
pubmed: 22426433
Cancer Res. 2013 Nov 1;73(21):6401-12
pubmed: 24041940
Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):E4134-41
pubmed: 24133140
Cell. 2013 Nov 7;155(4):948-62
pubmed: 24183448
Mayo Clin Proc. 2014 Mar;89(3):308-18
pubmed: 24486077
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44
pubmed: 25024180
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13409-14
pubmed: 25197050
Lancet Oncol. 2014 Dec;15(13):1521-32
pubmed: 25456371
Genes Dev. 2015 May 1;29(9):898-903
pubmed: 25934502
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Eur Urol. 2016 Apr;69(4):557-560
pubmed: 26563871
Nat Rev Clin Oncol. 2016 May;13(5):291-304
pubmed: 26598944
J Natl Cancer Inst. 2015 Nov 27;108(2):
pubmed: 26615022
N Engl J Med. 1989 Jul 20;321(3):129-35
pubmed: 2664509
Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):745-9
pubmed: 26941365
Nature. 2016 Mar 24;531(7595):471-475
pubmed: 26982726
Clin Cancer Res. 2017 Jan 1;23(1):81-87
pubmed: 27663590
Cancer Cell. 2017 Feb 13;31(2):240-255
pubmed: 28089890
Cancer. 2017 May 1;123(9):1490-1496
pubmed: 28152172
Eur Urol. 2018 Feb;73(2):178-211
pubmed: 28655541
PLoS Genet. 2017 Sep 25;13(9):e1007001
pubmed: 28945760
Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207
pubmed: 29141848
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):null
pubmed: 29311132
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Nat Genet. 2018 May;50(5):682-692
pubmed: 29662167
Nat Genet. 2018 Aug;50(8):1189-1195
pubmed: 30013179
Elife. 2018 Sep 04;7:
pubmed: 30178746